Blood test may guide treatment for relapsed kidney disease

NCT ID NCT05428605

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed lab study took blood samples from 20 adults with relapsed membranous nephropathy, a kidney condition. Researchers tested different immune-modulating drugs on the blood cells to see how they affect the balance of Th17 and Treg immune cells. The goal is to find which drug might work best for each patient based on their immune profile, but this is early research and not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors choose the best immune drug for patients with relapsed membranous nephropathy based on their immune profile.

What could go wrong

This is a very early lab study using blood samples, not a treatment trial. Results may not translate to real patient outcomes, and the small sample size limits generalizability.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTRAMEMBRANOUS GLOMERULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Nice

    Nice, 06200, France